NAELA Welcomes New Board Leadership for 2026-2027
VIENNA, Va., June 4, 2026 /PRNewswire/ -- The National Academy of Elder Law Attorneys (NAELA), the leading professional association dedicated...
EHR
IDBS i3 2026 forum in Boston showcases real-world customer outcomes in data-driven BioPharma
WOKING, United Kingdom, June 4, 2026 /PRNewswire/ -- IDBS, a Danaher company and leading provider of cloud software for BioPharma organizations,...
ChiroTouch and Aloha Form Preferred Partnership to Support Chiropractic Practices with Patient Engagement Solutions
The partnership connects ChiroTouch practices with Aloha's chiropractic-focused patient engagement platform, helping providers strengthen communication, improve front-office efficiency, and create...
Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting
FT819 off-the-shelf CAR T-cell therapy product candidate continues to broaden patient access with 21 SLE patients now treated, including as...
Elsevier acquires Wellsheet to close the gap between patient data and clinical evidence at the point of care
Elsevier's ClinicalKey AI and Wellsheet will deliver verifiable clinical evidence and patient context directly into the EHR, giving clinicians governed...
BayCare Expands Autonomous Hospital Delivery with New Relay Robots at Winter Haven Hospitals
The expanded robot fleet addresses the critical healthcare labor shortage by automating non-clinical logistics to prioritize nurse-to-patient bedside timeSAN JOSE,...
CVS Health: Mental Health Access Is Improving, Now Let’s Talk About Quality
NORTHAMPTON, MA / ACCESS Newswire / June 3, 2026 / Originally published on CVS Health Company NewsroomKey pointsTimely access to...
NRx Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock
WILMINGTON, Del., June 03, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals” or the “Company”), a clinical-stage...
Xcube.bio Strengthens Board with Appointment of Three Distinguished Non-Executive Directors
ZUG, Switzerland, June 03, 2026 (GLOBE NEWSWIRE) -- Xcubebio AG, a market entry acceleration engine for innovative biopharma and transformative...
Xcube.bio Strengthens Board with Appointment of Three Distinguished Non-Executive Directors
ZUG, Switzerland, June 03, 2026 (GLOBE NEWSWIRE) -- Xcubebio AG, a market entry acceleration engine for innovative biopharma and transformative...
New Expert Consensus Provides Age-Specific Guidance for Improving Care for Individuals with Genital Psoriasis Published in the American Journal of Clinical Dermatology
Expert recommendations focused on the diagnosis and management of genital psoriasis across age groups including pediatric, adult, and older populationsThis...
Palvella Therapeutics Announces Completion of FDA Pre-NDA Meeting for QTORIN™ Rapamycin in Microcystic Lymphatic Malformations
Palvella remains on track to submit an NDA in the second half of 2026 Microcystic lymphatic malformations are serious, chronic,...
Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Symptoms
All Evaluable Patients Achieved Improvements in Multiple Hallmarks of MYBPC3-Associated HCM Benefits Among Cohort 1 Patients Sustained as Far Out as...
PointClickCare Launches Advisor Suite, Expanding AI-Native Workflow Automation Solutions for Skilled Nursing
Billing Advisor added to suite of AI-informed solutions that unify data and help providers deliver exceptional careTORONTO, June 2, 2026...
Helix Builds North America’s Largest Available Linked Clinico-Genomic Dataset, Launches AI Tools to Accelerate Discovery
• Helix GenoSphere surpasses 500,000 clinico-genomic linked records, setting a new benchmark for scale in multi-modal research• Helix launches AI cohort...
Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML
– 87% ORR and 70% CRc in venetoclax-naïve and 48% ORR and 24% CRc in venetoclax-experienced patients at the recommended...
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Advancing Proprietary Solutions Focused on Nanotechnology-Enabled Drug Delivery, AI-Enhanced Biomedical Infrastructure
NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- via BioMedWire — Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement...
Cosmos Health Provides Balance Sheet Update: Highlights European Investment Bank Financing Discussions for up to €25M, Eliminates 38% of Warrant Overhang with No Dilution; Reaffirms Growth Trajectory; Notes No Known Business Reason for Recent Share Price Decline
Significant Deleveraging: Total liabilities decreased by $4.5 million, or 9.6%, quarter-over-quarter, while stockholders' equity increased 7.6%Landmark Financing: R&D division in...
Pluvicto™ demonstrated consistent efficacy across key patient subgroups in metastatic hormone-sensitive prostate cancer
Improved radiographic progression-free survival (rPFS) regardless of disease volume or metastatic presentation achieved with Pluvicto plus standard of care (ARPI...
Vor Bio to Participate in the 2026 Jefferies Global Healthcare Conference
BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune...